Products > RetinaVue

Simple, affordable and effective screening for diabetic retinopathy in your practice

RetinaVueTM Network from Welch Allyn gives you the power to improve management of your patients with diabetes. This low-cost, turnkey solution links to board-certified specialists for quick, easy-to-perform diabetic retinal screening during a routine patient visit. Compliance with annual retinal exams can reach 90% in one year using RetinaVue. You can help preserve patients' vision while also increasing your quality metrics and practice revenue.

Request a demo to learn how you can double patient compliance rates for diabetic retinal assessment in just 12 months with RetinaVue.

Benefits of bringing RetinaVue Network to your practice

With RetinaVue, you can easily and accurately screen for diabetic retinopathy as part of a patient's routine visit.

  • Simple to use: The handheld RetinaVue 100 imager is simple to use; any healthcare professional can obtain high-resolution fundus images in 5 minutes or less. A full diagnostic report is uploaded through a secure link. Results are typically available in 90 minutes from a board-certified retinal specialist. A simple 4-step process makes operation easy:

  • Affordable: At a price two-thirds less than desktop fundus cameras, the handheld RetinaVue 100 Imager makes retinal assessment in primary care settings practical. Four of the top five commercial healthcare payers provide coverage for RetinaVue diabetic retinopathy screening. Many providers enjoy a favorable return on investment within their first year. Coding options for digital retinal exams (DRE) include CPT codes 92250, 92227 and 92228. Verify specific reimbursement with your payer plans.
  • Effective: Patient compliance rates for diabetic retinal assessment can double in 12 months with RetinaVue, helping to preserve vision and increase quality metrics. Welch Allyn is the only nationwide diabetic retinopathy diagnostic services company exclusively using fellowship-trained, board-certified, retina specialists. Plus, annual diabetic retinal exams are included in the NCQA HEDIS, Medicare Advantage Stars and Medicare Medicare quality rating programs.

Download the white paper, "Improving Access to Potentially Vision-Saving Diabetic Retinopathy Screening Technology," to read more about practice benefits.

RetinaVue Network

RetinaVue Network includes: RetinaVueTM 100 Imager, the HIPAA-compliant RetinaVueTM Network and HIPPA-connected access to board-certified retina specialists.

RetinaVue Network product details:

  • Touchless image capture and autofocus technologies support ease of use
  • Integrated image quality assessment software
  • Automatic image evaluation helps ensure only high-quality fundus images are transmitted for evaluation
  • Fast, non-mydriatic exam promotes patient comfort
  • RetinaVue 100 Imager (portable fundas hand-held camera) with charging dock, reusable eye cup, USB cable, Lithium-ion 3.6 V battery and the 1-yr Partner in Care Program (includes training, 1-year warranty with over-night loaner coverage)
  • Frost & Sullivan recognized the Welch Allyn RetinaVue Network with the 2016 North America Frost & Sullivan Award for Customer Value Leadership
Download Brochure
Ready to bring the RetinaVue Network to your practice? Log in to SupplyManager to order today.
Log In to Buy

Early detection can help prevent vision loss

Diabetic retinopathy is the leading cause of blindness among working-age adults. Making diabetic retinal screening more accessible in primary care settings can improve early detection and enable timely, vision-saving treatment.

Diabetic retinopathy by the numbers:

  • 50% of people with diabetes do not get annual screening
  • 80% of patients with diabetes will develop diabetic retinopathy
  • 95% of vision loss cases can be prevented with early detection

Read more about how RetinaVue can benefit your diabetic patients and your practice.

* Patients with a documented retinal assessment, %

Garg S, Jani PD, Kshirsagar AV, King B, Chaum E. Telemedicine and Retinal Images for Improving Diabetic Retinopathy Evaluation. Arch Intern Med. 2012; Oct 1:1-2.

The product information contained in this document, including the product images and additional product materials, was collected from Welch Allyn. All product claims and specifications are those of the product suppliers, not McKesson Medical-Surgical or its affiliates ("McKesson") and have not been independently verified by McKesson. McKesson is not responsible for errors or omissions in the product information.

The properties of a product may change or be inaccurate following the posting or printing of the product information in the document, either in the print or online version. Caution should be exercised when using or purchasing any products from McKesson's online or print documents by closely examining the product packaging and the labeling prior to use.

Due to product changes, information listed in this document is subject to change without notice. This information is placed solely for your convenience in ordering and McKesson disclaims all responsibility for its completeness and accuracy, whether or not the inaccuracy or incompleteness is due to fault or error by McKesson.

Want to See RetinaVue in Action?

Request a Demo!

If you'd like to see how RetinaVue could work in your office, request a complimentary demo today and your Account Manager will contact you.
Request a Demo
Webinar Replay

Screening for Diabetic Retinopathy in Primary Care Settings

Originally aired July 13, 2016.

In this webinar, we examined:

  •  Annual diabetic retinal exam (DRE) compliance
  • The potential impact of DRE non-compliance on patient outcomes
  • Solutions to increase patient compliance, quality metrics and financial incentives
Watch Replay
JAMA Internal Medicine

Telemedicine and Retinal Imaging for Improving Diabetic Retinopathy Evaluation

"Telemedicine is an emerging strategy for improving diabetic retinopathy screening through retinal imaging with remote expert interpretation. Introducing this technology at the point of care physician could substantially reduce barriers and improve early detection of retinopathy."
Continue Reading
Login to McKesson